<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009787</url>
  </required_header>
  <id_info>
    <org_study_id>S2013-098-01</org_study_id>
    <nct_id>NCT02009787</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia</brief_title>
  <official_title>Effect of Vitamin D and Statins on Plasma Lipid Profiles in Chinese Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shi Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators planned to research the effect of vitamin D supplementation as an adjuvant
      therapy for patients with hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D is primarily generated in the skin, in response to direct absorption of ultraviolet
      B radiation. Vitamin D can also be obtained through fortified foods and oral supplements.
      Lipid abnormalities are common in the general population, and are regarded as a modifiable
      risk factor for cardiovascular disease. Recently low vitamin D status has been shown to be
      associated with increased risk of developing hyperlipidemia. Statins are normally the
      first-line therapy for hypercholesterolemia. It is also reported that vitamin D can improve
      serum lipid levels. However, its effects on hypercholesterolemia patients remain unclear. The
      investigators planned to determine the efficacy of combination therapy with statins and
      vitamin D in a cohort of hypercholesterolemia patients. This study may shed light as to
      whether oral vitamin D supplementation can be an adjunct therapy in hypercholesterolemia
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a change in serum total cholesterol level</measure>
    <time_frame>after 6 months of vitamin D supplementation</time_frame>
    <description>The primary end point was a change in serum total cholesterol level after 6 months of vitamin D supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>a change in serum triglycerides level</measure>
    <time_frame>after 6 months of vitamin D supplementation</time_frame>
    <description>The change in serum triglycerides level was measured after 6 months of vitamin D supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences in the incidences of treatment-emergent adverse events</measure>
    <time_frame>after 6 months of vitamin D supplementation</time_frame>
    <description>Treatment-emergent adverse events (TEAEs): hypercalcemia, renal insufficiency, constipation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Vitamin D supplementation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3 tablets</intervention_name>
    <description>2000 IU vitamin D3 tablets were taken daily for 6 months</description>
    <arm_group_label>Vitamin D supplementation group</arm_group_label>
    <other_name>Vigantoletten; Merck Pharma, Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo tablets</intervention_name>
    <description>2000 IU placebo tablets were taken daily for 6 months</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The main inclusion criteria were for hypercholesterolemia patients with the treatment of
        statins.

        Exclusion Criteria:

        The exclusion criteria were as follows: patients with chronic renal failure, chronic liver
        disease, bone disorders, and/or thyroid disorders. Patients were also excluded if they were
        taking vitamin D3 tablets or other lipid-regulating drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Tang Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Shi, M.D.</last_name>
    <phone>+8610-66876231</phone>
    <email>ggyyong@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Shi, M.D.</last_name>
      <phone>+8610-66876231</phone>
      <email>ggyyong@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yu Tang Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009 Jul;205(1):255-60. doi: 10.1016/j.atherosclerosis.2008.10.033. Epub 2008 Nov 11.</citation>
    <PMID>19091317</PMID>
  </reference>
  <reference>
    <citation>Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr. 2007 Oct;26(5):573-80. Epub 2007 Jul 10.</citation>
    <PMID>17624643</PMID>
  </reference>
  <reference>
    <citation>Skaaby T, Husemoen LL, Pisinger C, Jørgensen T, Thuesen BH, Fenger M, Linneberg A. Vitamin D status and changes in cardiovascular risk factors: a prospective study of a general population. Cardiology. 2012;123(1):62-70. doi: 10.1159/000341277. Epub 2012 Sep 12.</citation>
    <PMID>22986625</PMID>
  </reference>
  <reference>
    <citation>Ponda MP, Dowd K, Finkielstein D, Holt PR, Breslow JL. The short-term effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2510-5. doi: 10.1161/ATVBAHA.112.254110. Epub 2012 Sep 4.</citation>
    <PMID>22947589</PMID>
  </reference>
  <results_reference>
    <citation>Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther. 2009 Feb;85(2):198-203. doi: 10.1038/clpt.2008.165. Epub 2008 Aug 27.</citation>
    <PMID>18754003</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Shi Yang</investigator_full_name>
    <investigator_title>Director of Geriatric Cardiology</investigator_title>
  </responsible_party>
  <keyword>hypercholesterolemia; vitamin D; adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

